Billions boost next-generation weapons against SARS-CoV-2.

Area of Science:

• Immunology
• Vaccinology
• Infectious Disease

Background:

• The U.S. government is prioritizing specific vaccine and antibody technologies.
• Intranasal vaccines and monoclonal antibodies are central to current public health strategies.
• This approach focuses on established, albeit less ambitious, methods.

Discussion:

• The chosen strategies, intranasal vaccines and monoclonal antibodies, offer potential benefits for disease control.
• The omission of more ambitious approaches raises questions about long-term innovation in the field.
• Evaluating the limitations and potential of current investments is crucial.

Key Insights:

• Significant government funding is directed towards intranasal vaccines and monoclonal antibodies.
• The project's scope appears conservative, excluding more novel or complex interventions.
• A critical assessment of this strategic focus is warranted.

Outlook:

• Future research may need to address the overlooked ambitious approaches.
• Continued evaluation of the efficacy and impact of current investments is necessary.
• The long-term implications for public health preparedness remain to be seen.